IL6 and breast carcinoma: Previous studies have identified several FOSL1‐mediated stemness inducers such as IL‐6/STAT3 and SNAI3 in breast cancer, suggesting that drug resistance is induced by the FOSL1‐IL‐6/STAT3‐stemness axis [27, 28].